Primary Care
CMECNE

FDA Drug Safety Communication: Clarithromycin and Increased Potential Risk of Heart Problems or Death in Patients With Heart Disease

FavoriteLoading

Learning Objectives and CME/Disclosure Information

SUMMARY:  

FDA released a drug safety advisory and follow up review, advising caution before prescribing the antibiotic clarithromycin to patients with heart disease because of a potential increased risk of heart problems or death that can occur years later 

  • A review of the results from the CLARICOR trial,  a 10-year follow-up study of patients with stable coronary heart disease from a large clinical trial, observed this serious safety issue 
  • More deaths were observed in patients who underwent a two-week course of clarithromycin that became apparent after ≥1 year of follow up  
    • No clear explanation was apparent as to why clarithromycin would lead to more deaths than placebo 
    • Observational studies have been conflicting   
  • The FDA  
    • Has added a new warning about this increased risk of death in patients with heart disease that also advises prescribers to consider using other antibiotics in such patients 
    • Has added the study results to the clarithromycin drug labels 
    • Will continue to monitor safety reports in patients taking clarithromycin 
  • FDA recommends the following  

Healthcare professionals should be aware of these significant risks and weigh the benefits and risks of clarithromycin before prescribing it to any patient, particularly in patients with heart disease and even for short periods, and consider using other available antibiotics. Advise patients with heart disease of the signs and symptoms of cardiovascular problems, regardless of the medical condition for which you are treating them with clarithromycin.

KEY POINTS:  

  • Clarithromycin is used to treat many types of infections including  
    • Those affecting the skin, ears, sinuses and lungs   
    • Helicobacter pylori 
    • Mycobacterium avium complex (MAC) infection which can be seen in individuals with HIV  
  • In the CLARICOR study, there was increased all-cause mortality and CVD during 10 year follow up, primarily in patients not on statin at entry 
  • FDA recommends that patients talk to their provider about benefits and risks of clarithromycin and any alternative treatments 
  • Patients should  
    • Be alert to signs or symptoms of stroke or MI  
    • Should not stop taking medications without medical discussion and oversight  
  • Adverse events or side effects should be reported to FDA’s MedWatch Safety Information and Adverse Event Reporting Program 
    • Online: www.fda.gov/MedWatch/report  
    • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 

Learn More – Primary Sources:  

FDA Drug Safety Communication: FDA review finds additional data supports the potential for increased long-term risks with antibiotic clarithromycin (Biaxin) in patients with heart disease

Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the CLARICOR randomised, blinded clinical trial 

 

Take a post-test and get CME credits

Want to be notified when new guidelines are released? Get ObGFirst!

ObGFirst® – Try It Free! »

FavoriteLoading

Related ObG Topics:

Practical info on evidence based medicine for your women's healthcare practice
Does Estrogen Therapy Have Cardiovascular Benefit in Early Postmenopause?
Patient with Stable CVD: Rivaroxaban, Aspirin or Both to Prevent Recurrent Events?
Familial Hypercholesterolemia: A Reportable ACMG Secondary Finding

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month